Pharmaceutical industry – Page 37
-
BusinessUnpicking doctor payments
Accepting even small meals from drug industry reps appears to influence doctors’ prescription rates
-
BusinessAstraZeneca licenses skin drugs to Leo
Offloading psoriasis and dermatitis antibodies continues AZ’s plan to refocus on fewer therapy areas
-
BusinessNovartis partners with Xencor for cancer antibodies
Deal deepens Novartis’s focus on immuno-oncology
-
BusinessLies and deception see Astellas UK suspended by trade body
Company promoted drugs inappropriately and misled regulators in the resulting investigation
-
BusinessSanofi and Boehringer agree €11bn asset swap
Deal swaps Sanofi’s animal health arm for Boehringer’s consumer healthcare business as both firms aim to boost scale
-
BusinessHarvard settles with ex-student over drug royalties
Student claimed university forced him to accept unfair cut in patent deal
-
Business
Teva sells off products in preparation for Allergan merger
Generics deals with Impax, Dr Reddy’s and Sagent aimed at satisfying competition authorities
-
BusinessUS biotech director accused of insider trading
Biostatistics chief at Akebia charged with securities fraud
-
BusinessJudge voids Merck & Co’s $200m patent claim
‘Serious misconduct’ kills case over Gilead’s hepatitis C drugs
-
BusinessAdventures of an accidental entrepreneur
India needs to break out of its colonial mindset and tap into its innovative potential, says Biocon chief Kiran Mazumdar-Shaw
-
Business
Merck & Co to buy Afferent for neurology drugs
Deal worth up to $1.25bn includes drug candidate for chronic coughs
-
ResearchConnections in flow
MIT’s Klavs Jensen tells us how his research ranges in size from a chip, to a fridge to a shipping container
-
BusinessJazz Pharma buy out Celator in $1.5bn deal
Deal centres on promising leukaemia drug fast-tracked by the US Food and Drug Administration
-
BusinessIndia hit hard by US regulatory sanctions
Data integrity issues have led to punitive measures, but companies are taking measures to improve
-
-
BusinessMylan expands in dermatology
$1bn deal with Renaissance Acquisition Holdings brings 25 products and builds on Meda merger portfolio
-
BusinessPfizer to buy Anacor for eczema ointment
$5.2bn deal will bolster pharma giant’s inflammation and immunology drugs portfolio
-
-
BusinessDaiichi Sankyo awarded damages from former Ranbaxy owners
Arbitration says Singh family withheld information about regulatory investigations during Ranbaxy takeover
-
BusinessAbbot boosts heart devices with St Jude buyout
Medical devices consolidation continues with $25bn deal, but Abbott expresses concerns over proposed Alere merger